Cyclops®

  • Convenient
  • Reliable
  • Easy-to-use
  • Easy-to-carry
  • Hygienic
  • Less Cough

Cannovex and PureIMS Announce Strategic Co-Development Agreement for Inhaled Cannabinoid Pharmaceuticals

PureIMS

Cannovex and PureIMS Announce Strategic Co-Development Agreement for Inhaled Cannabinoid Pharmaceuticals

| Posted on |

Cannovex and PureIMS Announce Strategic Co-Development Agreement for Inhaled Cannabinoid Pharmaceuticals

Download a copy of this press release here. Diepenbeek, Belgium and Roden, The Netherlands, March 13, 2026 – Cannovex and PureIMS have entered into a strategic partnership to develop innovative pharmaceutical cannabinoid products. The collaboration combines Cannovex’s proprietary cannabinoid formulations with PureIMS’s patented Cyclops® dry powder inhaler (DPI). Under the terms of the agreement, Cannovex […]

PureIMS secures a European grant to develop a new dry powder inhaler

| Posted on |

PureIMS secures a European grant to develop a new dry powder inhaler

  PureIMS receives a grant of € 41.028,58 to initiate the development of a new dry powder inhaler (DPI). This new DPI will contain an innovative dispersion mechanism to enable delivery of medicines such as antibiotics, vaccines, and biologics. Unlike current devices, it will be user-friendly and suitable for vulnerable groups like children and elderly […]

An In Vitro–In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops

| Posted on |

An In Vitro–In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops

Full paper: Pharmaceutics 2025, 17(9), 1149; https://doi.org/10.3390/pharmaceutics17091149 Background/Objectives: The pulmonary administration of levodopa enables a rapid absorption and onset of action, making it a suitable administration route for managing OFF episodes in Parkinson’s disease. Currently, one dry powder product for inhalation (Inbrija) is available on the market, while another (Levodopa Cyclops) is in development. These […]

Protected: CYCLOPS® Dry Powder Inhaler Now Available Nationwide in the Netherlands Thanks to Agreement Between Fagron and PureIMS

| Posted on |

Protected: CYCLOPS® Dry Powder Inhaler Now Available Nationwide in the Netherlands Thanks to Agreement Between Fagron and PureIMS

There is no excerpt because this is a protected post.

International Congress of Parkinson’s Disease and Movement Disorders 2024 – poster on Levodopa Cyclops®

| Posted on |

International Congress of Parkinson’s Disease and Movement Disorders 2024 – poster on Levodopa Cyclops®

Please check out our latest poster (#708) presenting clinical study results of a head-to-head comparison between Levodopa Cyclops® and Inbrija®. Highlights are: Levodopa Cyclops® is safe and very well tolerated (no cough). Levodopa absorption from Cyclops® is comparable to Inbrija®, thereby, fulfilling the bioequivalence criteria. Results enable abbreviated registration routes with a limited – PK-only […]

PureIMS gears up for abbreviated registration of Levodopa Cyclops® against OFF episodes in Parkinson’s disease with the successful completion of a comparative pharmacokinetic study

| Posted on |

PureIMS gears up for abbreviated registration of Levodopa Cyclops® against OFF episodes in Parkinson’s disease with the successful completion of a comparative pharmacokinetic study

Roden, the Netherlands, January 18, 2024 PureIMS, a pharmaceutical company focused on the development of innovative inhalation products, this week reported it has completed a comparative pharmacokinetic study with Levodopa Cyclops®. The study results show rapid pulmonary absorption of levodopa in absence of safety and tolerability issues. These properties make Levodopa Cyclops® a prime candidate […]

PureIMS winning the LIFE Science Innovation Award!

| Posted on |

PureIMS winning the LIFE Science Innovation Award!

Tuesday September 26 was an exciting day for the PureIMS team. Not only was the first cohort of volunteers dosed in the penultimate Levodopa Cyclops™ bioavailability study, we were also honored with the LIFE Science Innovation Award. LIFE Cooperative, very successfully organizing their annual conference and award ceremony, is a cooperation of 50+ LifeScience and MedTech SMEs […]